Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2025-05-20 DOI:10.1016/j.clgc.2025.102378

Simon U. Engelmann , Christoph Pickl , Maximilian Haas , Felix Kasparbauer , Emily Rinderknecht , Sebastian Kälble , Bas W.G. van Rhijn , Peter J. Siska , Sonja-Maria Decking , Kathrin Renner , Renate Pichler , Maximilian Burger , Miodrag Gužvić , Roman Mayr

{"title":"Prognostic Role of Serum IL-6 Levels in Bladder Cancer Patients and Hints of its Origin","authors":"Simon U. Engelmann , Christoph Pickl , Maximilian Haas , Felix Kasparbauer , Emily Rinderknecht , Sebastian Kälble , Bas W.G. van Rhijn , Peter J. Siska , Sonja-Maria Decking , Kathrin Renner , Renate Pichler , Maximilian Burger , Miodrag Gužvić , Roman Mayr","doi":"10.1016/j.clgc.2025.102378","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue.</div></div><div><h3>Methods</h3><div>In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA.</div></div><div><h3>Results</h3><div>Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; <em>P</em> = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; <em>P</em> = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all <em>P</em> < .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage (<em>P</em> < .01).</div></div><div><h3>Conclusions</h3><div>Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention.</div></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"23 4","pages":"Article 102378"},"PeriodicalIF":2.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical genitourinary cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767325000783","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Interleukin-6 (IL-6) is associated with adverse clinical outcome in cancer patients. In bladder cancer (BC) patients, higher IL-6 serum levels have been linked with adverse pathologic features, worse overall survival (OS) and cancer-specific survival (CSS). IL-6 is being investigated as a therapeutic target. However, concentrations in tumor-tissue are not investigated in detail. Objective of this study is to analyze the prognostic value of IL-6 in BC patients and to investigate its concentration in tumor tissue.

Methods

In this single center prospective observational study, preoperative serum samples of 179 BC patients undergoing radical cystectomy were collected between September 2019 and September 2022. Tumor-tissue of additional 20 patients was collected during transurethral resection or radical cystectomy for investigation of IL-6 in tumor tissue supernatant. IL-6 concentration was measured by ELISA.

Results

Median serum IL-6 concentration was 5.4 pg/mL. High serum IL-6 was an independent predictor of OS (HR 1.95; 95% CI, 1.07-3.55; P = .03) and CSS (HR 2.31; 95% CI, 1.14-4.68; P = .02) in multivariate Cox regression analyses. Patients with advanced tumor stage, lymph node metastasis, and larger tumor size had significantly higher preoperative serum IL-6 concentration (all P < .01). In tumor tissue supernatant, IL-6 concentration was higher in muscle-invasive BC, with a median of 715.4 pg/mL, as opposed to 20.7 pg/mL in pTa tumor stage (P < .01).

Conclusions

Serum IL-6 is a strong predictor of poor survival rates and adverse pathologic features in BC patients. IL-6 concentrations in tumor tissue supernatant correlate with tumor stage. The role of IL-6 in theranostics of bladder cancer deserves more attention.

查看原文本刊更多论文

血清IL-6水平在膀胱癌患者预后中的作用及其来源提示。

背景：白细胞介素-6 （IL-6）与癌症患者的不良临床结局相关。在膀胱癌（BC）患者中，较高的血清IL-6水平与不良病理特征、更差的总生存期（OS）和癌症特异性生存期（CSS）有关。目前正在研究IL-6作为一种治疗靶点。然而，肿瘤组织中的浓度没有详细研究。本研究的目的是分析IL-6在BC患者中的预后价值，并探讨其在肿瘤组织中的浓度。方法：在这项单中心前瞻性观察研究中，收集2019年9月至2022年9月期间接受根治性膀胱切除术的179例BC患者的术前血清样本。另外20例患者经尿道切除或根治性膀胱切除术时取肿瘤组织，研究肿瘤组织上清液中IL-6的含量。ELISA法检测IL-6浓度。结果：血清中位IL-6浓度为5.4 pg/mL。高血清IL-6是OS的独立预测因子(HR 1.95；95% ci, 1.07-3.55；P = .03)和CSS (HR 2.31；95% ci, 1.14-4.68；P = .02)。肿瘤分期晚期、淋巴结转移、肿瘤体积较大的患者术前血清IL-6浓度显著高于其他患者（均P < 0.01）。在肿瘤组织上清液中，IL-6浓度在肌肉浸润性BC中较高，中位数为715.4 pg/mL，而在pTa肿瘤期中为20.7 pg/mL （P < 0.01）。结论：血清IL-6是BC患者低生存率和不良病理特征的一个强有力的预测因子。肿瘤组织上清中IL-6浓度与肿瘤分期相关。IL-6在膀胱癌治疗中的作用值得关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.